S. Feng

发表

Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2010 .

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2017, Leukemia & lymphoma.

Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS)

D. Sargent, J. Berlin, A. Grothey, 2008 .

Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE observational cohort study (OCS)

D. Sargent, J. Berlin, A. Grothey, 2008 .

Use and Evaluation of a CD-ROM-Based Decision Aid for Prostate Cancer Treatment Decisions

M. Schwartz, A. Dritschilo, Randi M. Williams, 2010, Behavioral medicine.

Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)

S. Russell, H. Goldschmidt, M. Dimopoulos, 2015 .

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

H. Goldschmidt, M. Dimopoulos, R. Hájek, 2017, The Lancet. Oncology.

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

H. Goldschmidt, D. Siegel, P. Hari, 2017, Leukemia.

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

H. Lenz, H. Hurwitz, L. Saltz, 2015, Journal of the National Cancer Institute.

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, Leukemia.

Carfilozomib versus bortezomib for relapsed or refractory myeloma - Authors' reply.

M. Dimopoulos, A. Palumbo, P. Moreau, 2016, The Lancet. Oncology.

What is the impact of shared decision making on treatment and outcomes for older women with breast cancer?

J. Mandelblatt, B. Kreling, S. Feng, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

W. Novotny, Jianda Hu, R. Feng, 2020, Journal of Hematology & Oncology.

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion

P. Ganly, S. Opat, C. Tam, 2020, Haematologica.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, The Lancet. Oncology.

Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib.

J. Burke, I. Flinn, T. Guthrie, 2021, Journal of Clinical Oncology.

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study

H. Rugo, D. Tripathy, D. Yardley, 2012, Breast Cancer Research and Treatment.

PS1159 POOLED ANALYSIS OF SAFETY DATA FROM MONOTHERAPY STUDIES OF THE BRUTON TYROSINE KINASE (BTK) INHIBITOR, ZANUBRUTINIB (BGB-3111), IN B-CELL MALIGNANCIES

W. Novotny, P. Marlton, A. Roberts, 2019, HemaSphere.

M. Dimopoulos, R. Hájek, P. Moreau, 2019, Blood Cancer Journal.

Exploring racial differences in outcome and treatment for metastatic colorectal cancer

D. Sargent, J. Berlin, A. Grothey, 2012, Cancer.

Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2010 .

Exploring racial differences in outcome for metastatic colorectal cancer: Results from a large prospective observational cohort study (BRiTE).

B. Polite, M. Kozloff, A. Sing, 2010 .

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, Leukemia.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2011, Journal of Clinical Oncology.

M. Dimopoulos, P. Moreau, H. Ludwig, 2016 .

Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

H. Goldschmidt, M. Dimopoulos, R. Orlowski, 2018, Leukemia & lymphoma.

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

M. Dimopoulos, R. Hájek, P. Moreau, 2019, Blood Cancer Journal.

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.

Deepak L. Bhatt, P. Bedossa, K. Kowdley, 2023, The New England journal of medicine.

P1-08-22: Treatment Patterns and Clinical Outcomes in Elderly Patients with HER2−Positive Metastatic Breast Cancer from the registHER Observational Study.

H. Rugo, D. Tripathy, D. Yardley, 2011 .

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

J. Kastelein, K. Wasilewska, J. E. Cain, 2023, Nature Medicine.

Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial

M. Dimopoulos, J. Keats, A. Oriol, 2017 .

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

C. Tam, Xiaoping Zhang, J. Trotman, 2017 .